{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-418538","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-10-09T11:59:32+00:00","discovered_at":"2026-10-09T12:00:00.548271+00:00","generated_at":"2026-10-12T15:18:26.059001+00:00","sec_items":["5.02","5.03","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quince Therapeutics renamed IRulya; Roberts named CEO, Militello CFO, Fandrick COO effective Oct 8, 2026","bullets":["Brigette Roberts, M.D. became CEO effective Oct 8, 2026 with $600,000 base salary and 50% target bonus; John Militello, CPA became CFO and Keith Fandrick, Ph.D. became COO.","Dirk Thye resigned as CEO, CMO and director and Brendan Hannah resigned as COO, CBO and CCO; June Bray, David Lamond, Christopher Senner and Thye also left the Board with no disagreements.","Name change to IRulya Therapeutics Inc. is effective 4:01 p.m. ET Oct 9, 2026; common stock moves to Nasdaq Capital Market under IRLA effective Oct 12, 2026, with CUSIP unchanged.","Cash balance was $116 million as of June 30, 2026 and is expected to fund operations through end of 2028, supporting Phase 2 data readouts for LAM-001 in BOS, PH-ILD and SAPH.","Board added Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise effective Oct 8, 2026; Patterson chairs Audit/Compensation, Valentine chairs Governance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-418538","json":"https://secwatch.observer/filing/0001193125-26-418538.json","markdown":"https://secwatch.observer/filing/0001193125-26-418538.md","text":"https://secwatch.observer/filing/0001193125-26-418538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/d172110d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:18:26.059001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0026c01213","claim":"Dirk Thye resigned as Chief Executive Officer, Chief Medical Officer and Director at Quince Therapeutics, Inc..","evidence_excerpt":"effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer, Chief Medical Officer and Director"}],"fact_type":"executive_change"},{"claim_id":"7487fffedc","claim":"Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer, Chief Business Officer and Chief Compliance Officer"}],"fact_type":"executive_change"},{"claim_id":"f12966ed58","claim":"Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Effective October 8, 2026 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}